Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne ...
12 analysts have shared their evaluations of Avidity Biosciences (NASDAQ:RNA) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...
Avidity BiosciencesRNA saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 80 to 93. Please watch the video at Investors.com - What Are The Magnificent Seven ...
Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Avidity Biosciences (RNA – Research Report). The associated price target remains the same with $50.00. Yanan Zhu has given his Buy ...
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and ...
Novartis AG will acquire Avidity Biosciences, Inc. for $12bn, aiming to strengthen its neuroscience franchise and xRNA strategy with late-stage muscle disease assets. The deal brings three late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results